

Supplemental Table 2. Relative risk of incident fracture in ZOL vs. placebo for those who developed APR and those who did not

Type of incident fracture	RR ^a (95% CI) of fracture for ZOL vs. Placebo			<i>p</i> value for interaction
	APR+	APR-	All Women	
Morphometric vertebral fracture				
Unadjusted	0.19 (0.12, 0.31)	0.38 (0.30, 0.49)	0.30 (0.24, 0.38)	0.01
Adjusted ^b	0.22 (0.14, 0.35)	0.37 (0.29, 0.47)		0.05
Non-vertebral fracture				
Unadjusted	0.73 (0.51, 1.05)	0.80 (0.67, 0.96)	0.75 (0.64, 0.87)	0.67
Adjusted ^b	0.74 (0.51, 1.07)	0.78 (0.65, 0.93)		0.94
Hip fracture				
Unadjusted	0.71 (0.30, 1.70)	0.65 (0.44, 0.97)	0.59 (0.42, 0.83)	0.86
Adjusted ^b	0.79 (0.32, 1.96)	0.59 (0.39, 0.88)		0.59

APR = acute-phase reaction; CI = confidence interval; RR = relative risk; ZOL = zoledronic acid.

^a Odds ratio for vertebral fractures using logistic regression, relative hazard for non-vertebral and hip fractures using Cox proportional hazard models.

^b Adjusted for race (Asian or non-Asian), age, prior bisphosphonate usage, active back pain, diabetes, femoral neck BMD, number of prevalent vertebral fractures, creatinine clearance, alkaline phosphatase.